Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

SSRIs do not increase cataract risk

30 Jun 2017

Selective serotonin reuptake inhibitors (SSRIs) do not appear to promote the development of cataract in users, according to a case-control study.

Researchers examined 206,931 cataract patients aged ≥40 years and similar number of matched controls. Data on the number of SSRI prescriptions and prescriptions for other antidepressant drugs were obtained and analysed using conditional logistic regression. Adjustments were made for body mass index, smoking, hypertension, diabetes and systemic steroid use.

Results showed no association between current long-term use of SSRI (≥20 prescriptions) and an increased cataract risk (adjusted odds ratio [OR], 0.99; 95 percent CI, 0.94 to 1.03). However, in a subset of patients aged 40 to 64 years, long-term SSRI users demonstrated a slightly increased risk of cataract compared with nonusers (adjusted OR, 1.24; 1.15 to 1.34).

The observed increase, however slight, in the odds of developing cataract among long-term SSRI users aged 40 to 64 years warrant additional studies, researchers said.

A monoamine neurotransmitter found primarily in the gastrointestinal tract and the central nervous system, serotonin functions to regulate mood, appetite and sleep. It is also located in the aqueous humour of patients with ocular complications such as cataracts and glaucoma, and serotonin binding proteins are found in the lens of animals. [Can J Ophthalmol 2014;49:e112–e114]

While not fully understood, the mechanism underlying the association between serotonin and cataract is said to potentially involve melatonin (one of the downstream products of serotonin), although the hormone plays a protective role. Melatonin is sequentially synthesized from serotonin in the pineal gland and functions in the regulation of the circadian system. The hormone also acts in the ocular lens as an antioxidant and radical scavenger, and has been shown to protect against cataract formation in rats. [Can J Ophthalmol 2014;49:e112–e114]

Although having a relatively good safety profile and few reported ophthalmologic sequelae resulting from their use, several studies have reported that serotonin, melatonin and their receptors have a role in cataractogenesis. This highlights the possibility of SSRIs affecting the concentration of serotonin and melatonin in the aqueous humour. [J Pineal Res 2007;42:92-6; Mol Vis 2008;14:2143-7]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.